Skip to main content
Figure 2 | BMC Neuroscience

Figure 2

From: Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson’s disease

Figure 2

Effects of mirtazapine on the striatal dopamine, DOPAC and HVA contents. Values are expressed as means ± SEM, n = 5 mice/group. Mirt.(4), mirtazapine 4 mg/kg; Mirt.(16), mirtazapine 16 mg/kg. Statistical significance was evaluated by one-way ANOVA followed by Student-Newman-Keuls test (F(DA) 4,20 = 15.423, F(DOPAC) 4,20 = 10.767, F(HVA) 4,20 = 6.643, F(Turnover) 4,20 = 4.951, *P < 0.05, **P < 0.01 compared with MPTP-treated group) or by Student’s t-test (##P < 0.01 compared with vehicle group).

Back to article page